The pharmaceutical industry has urged the government to agree a Brexit deal that prevents harm to clinical trials in the UK, after a trial for a heart drug was put on hold.
The Association of the British Pharmaceutical Industry said it was “absolutely vital” that the UK and the European Union reached a withdrawal agreement to maintain the skills, resources and investment put into UK clinical trials.
The trade group issued its call after the Golden Jubilee Foundation—a Glasgow-based group of NHS facilities—announced that the California-based medical research firm Recardio had put a clinical trial for a heart drug on hold in the UK because of concerns over Brexit. The company was about to try the drug, dutogliptin, at UK sites including the Golden Jubilee National Hospital, near Glasgow.
This article on Research Professional News is only available to Research Professional or Pivot-RP users.
Research Professional users can log in and view the article via this link
Pivot-RP users can log in and view the article via this link.